Please enter the email address you used to register, then we will send you a link to choose a new password
Dermata Therapeutics (NASDAQ:DRMA) reported quarterly losses of $(4.18) per share which missed the analyst consensus estimate o...
- Reuters
-SEC Filing
Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnolog...
Dermata Therapeutics (NASDAQ:DRMA) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate o...